middle.news
How Prescient’s $9.8M Raise Fuels PTX-100’s Fight Against Lymphoma
9:15am on Friday 10th of October, 2025 AEDT
•
Healthcare
Read Story
How Prescient’s $9.8M Raise Fuels PTX-100’s Fight Against Lymphoma
9:15am on Friday 10th of October, 2025 AEDT
Key Points
Completed $9.8 million capital raise via placement and share purchase plan
Cash balance increased to $12.32 million at September 30, 2025
Phase 2a clinical trial enrolment underway across Australia, Europe, and the US
Phase 1b sub-analysis in Cutaneous T Cell Lymphoma shows 43% overall response rate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE